LivaNova reports 36‑month CORE‑VNS results showing 76% median seizure reduction and 73% drop in hospitalizations
LivaNova PLC released the full 36‑month outcomes of its CORE‑VNS observational study of VNS Therapy in drug‑resistant epilepsy. The data show a 76% median reduction in seizure frequency and a 73% reduction in seizure‑related hospitalizations, with 64% of patients achieving at least a 50% seizure drop. The study enrolled 531 participants, of whom 426 completed the full follow‑up, representing an 80% retention rate.
Why it matters
The company says the results demonstrate long‑term effectiveness and safety of its VNS Therapy, which could increase adoption by epilepsy centers and support future revenue growth. No analyst commentary was provided in the materials.
Key facts
- 1Median seizure frequency was reduced by 76% from baseline over 36 months. finanznachrichten.de
- 264% of participants achieved at least a 50% reduction in seizure frequency. finanznachrichten.de
- 373% reduction in seizure‑related hospitalizations compared with baseline. stocktitan.net
- 4The study included 531 participants, with 426 completing 36‑month follow‑up. stocktitan.net
- 5Retention rate at 36 months was 80%. finanznachrichten.de
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.